Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib | Zendy

Steffen Böhm | Zendy; Dagmar Hess | Zendy; Silke Gillessen | Zendy; Michael Brändle | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib

Author(s) -

Steffen Böhm,

Dagmar Hess,

Silke Gillessen,

Michael Brändle

Publication year - 2010

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc10-0436

Subject(s) - pazopanib , medicine , prostate cancer , tyrosine kinase , tyrosine kinase inhibitor , oncology , glycemic , growth factor receptor , sunitinib , pharmacology , diabetes mellitus , endocrinology , cancer , receptor

Pazopanib is a novel antiangiogenic inhibitor of tyrosine kinases (TKIs) with high activity against vascular endothelial growth factor receptor (VEGFR1–3), platelet-derived growth factor receptor (PDGFRα+β), and c-Kit. Here we report on a patient with prostate cancer and type 2 diabetes whose glycemic control has been significantly improved with pazopanib during anticancer therapy and describe a potential mechanism of action.The 73-year-old patient was diagnosed with prostate cancer in 1999 and underwent prostatectomy and radiotherapy, sequential hormonal therapies, and, in 2008, first line chemotherapy. Due to disease progression he was enrolled in a phase I trial with pazopanib (400 mg p.o. daily, day 1 to 21 every 3 weeks) in combination with epirubicine (75 mg/m2 i.v. q3w …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research